Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a […] The post Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer appeared first on Web-Release.

    Travellers are increasingly prioritising wellbeing, preventative healthcare and meaningful experiences over traditional holidays amid recent global uncertainty. The Tourism Authority of Thailand (TAT) has introduced ‘Healing is the New Luxury,’… The post Thailand Introduces ‘Healing Is The New Luxury’ To Meet Growing GCC Demand For Wellness And Medical Travel appeared first on Web-Release.